01—Abstract
Summary
Summary of the 8-K filed March 29, 2024. Cited figures are marked; the original filing is the authoritative source.
United Therapeutics Corporation filed this Current Report on Form 8-K dated March 29, 2024 to disclose an extension of its Credit Agreement, originally entered into on March 31, 2022 with certain subsidiary guarantors, the lenders named therein, and Wells Fargo Bank, National Association, as administrative agent and swingline lender.
The Credit Agreement provides an unsecured revolving credit facility of up to $1.2 billiona and a second unsecured revolving credit facility of up to $800 million, which may be increased by up to $500 million in the aggregate subject to lender commitments and other conditions. The filing states that the Company exercised its first one-year extension option on March 31, 2023, and that, under Section 2.7 of the Credit Agreement, the maturity of each lender's commitments and loans has now been extended by one additional year to March 31, 2029, effective March 29, 2024. The filing notes that the lenders' extension right is limited to a maximum of two such one-year extensions.
The filing is brief and is limited to this maturity extension under Items 1.01 and 2.03, which incorporate the extension information by reference. Full terms of the Credit Agreement are in the exhibit to the Company's April 1, 2022 Form 8-K, which the filing incorporates by reference.
02—Key points
Key Highlights
- Credit Agreement maturity extended by one additional year, from March 31, 2028 to March 31, 2029, effective March 29, 2024.
- Unsecured revolving credit facility of up to $1.2 billion under the Credit Agreement.
- Second unsecured revolving credit facility of up to $800 million under the Credit Agreement.
- Facilities may be increased by up to $500 million in the aggregate, subject to lender commitments and other conditions.
- This is the second of up to two one-year lender extensions permitted under the agreement, following the extension exercised on March 31, 2023.
- Wells Fargo Bank, National Association serves as administrative agent and swingline lender.
- The filing is reported under Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation).
03—Questions
Frequently Asked Questions
What changed in the Credit Agreement in this filing?
The maturity of each lender's commitments and loans was extended by one additional year, to March 31, 2029. The extension became effective March 29, 2024, under Section 2.7 of the Credit Agreement.
How large are the revolving credit facilities?
The Credit Agreement provides an unsecured revolving credit facility of up to $1.2 billion and a second unsecured revolving credit facility of up to $800 million. The facilities may be increased by up to $500 million in the aggregate, subject to obtaining commitments from lenders and other conditions.
Is the credit facility secured?
No. The filing describes both revolving credit facilities as unsecured.
How many extensions can the lenders provide?
The filing states that the lenders may elect to extend the maturity of their commitments by one year following a Company request, up to a maximum of two such extensions. The first was exercised on March 31, 2023, and this filing reports the second.
Where can I find the full terms of the Credit Agreement?
The filing incorporates by reference the copy of the Credit Agreement attached as Exhibit 10.1 to the Company's Current Report on Form 8-K filed April 1, 2022.
04—Continue